What Are the Priorities for the Patient with Renal Impairment and Hypercalcemia?
Release Date: August 14, 2014
Expiration Date: August 14, 2015
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Advances in multiple myeloma have extended survival nearly three-fold in the past decade with the availability of novel therapies, but patients with poor risk genetic features, heavy disease burden, extensive end organ involvement including renal impairment, hypercalcemia, anemia and bone lesions, as well as comorbidities, represent 20-40% of all newly diagnosed patients. While clinical development continues at a rapid pace, community oncology practitioners are challenged to remain current with these advances in addition to having relatively little practical experience managing this incurable small population hematologic malignancy. While clinical guidelines may instruct which tests should be performed and which agents are standard of care, they do not provide management skills essential to effective multiple myeloma patient care.
This activity is designed for physicians, pharmacists, and physician assistants who have an interest in enhancing their clinical skills in managing patients with multiple myeloma already presenting with renal insufficiency.
Upon completion of this educational activity, participants should be able to:
- Interpret the initial diagnostic work-up test results for multiple myeloma
- Apply risk-stratification models to determine prognosis of newly diagnosed multiple myeloma patients
- Develop individualized treatment plans for newly diagnosed myeloma patients with poor-risk genetic features, heavy disease burden, extensive end organ involvement, and common comorbidities
What are the priorities for the patient with renal impairment and hypercalcemia? – David Vesole, MD, PhD, FACP
Instructions for Participation and Credit
This activity is eligible for credit through August 14, 2015. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
David H. Vesole, MD, PhD, FACP
Co-Director, Myeloma Division
Director, Myeloma Research
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey
Dr. David Vesole earned his doctorate degree in immunology at the Medical University of South Carolina, Charleston, and his medical degree from Northwestern University Medical School, Chicago. He was a postdoctoral fellow in the Department of Microbiology and Immunology at the University of Colorado Health Sciences Center, as well as a resident in internal medicine, and a fellow in hematology/oncology at the University of Iowa Hospitals and Clinics. Dr. Vesole is currently co-director, myeloma division, and director, myeloma research at the John Theurer Cancer Center at Hackensack University Medical Center. In addition, he is a professor of medicine in the Department of Medicine at the University of Medicine & Dentistry of New Jersey, Newark, New Jersey, and at Georgetown University, Washington, DC.
Dr. Vesole is board certified by the American Board of Internal Medicine, the National Board of Medical Examiners, and holds memberships in the American College of Physicians, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology, and the Myelodysplastic Syndromes Foundation. In addition, Dr. Vesole is on the Board of Directors of the Leukemia & Lymphoma Society (Wisconsin and New York affiliates).
A nationally recognized multiple myeloma expert, Dr. Vesole specializes in stem cell transplant for the treatment of multiple myeloma and other hematological diseases. He has authored hundreds of articles, abstracts and book chapters in peer-reviewed medical journals.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for .5 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-14-022-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. David Vesole has received honoraria related to speakers’ bureau activities from Celgene Corporation, Millennium: The Takeda Oncology Company, and Onyx.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Vesole has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Vesole has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation.
©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.